Institutional members access full text with Ovid®

Share this article on:

Telavancin for MRSA Endocarditis: Case Report and Review of the Literature

Majumdar, Rohit MD*; Crum-Cianflone, Nancy F. MD, MPH*†‡

Infectious Diseases in Clinical Practice: July 2017 - Volume 25 - Issue 4 - p 176–183
doi: 10.1097/IPC.0000000000000470
Review Articles

Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) endocarditis refractory to standard therapies is an increasingly prevalent clinical entity. Telavancin is a newly developed lipoglycopeptide with potent activity against MRSA, but few data exist regarding its potential role for MRSA endocarditis. We report a case of MRSA persistent bacteremia and endocarditis successfully treated with telavancin after failing standard agents due to multiple adverse effects. Additionally, we summarize the patient characteristics, clinical courses, and outcomes of all 15 published cases of MRSA endocarditis treated with telavancin in the peer-reviewed literature. These cases demonstrate telavancin's potential role in the treatment of MRSA invasive endovascular infections in the setting of refractory disease.

Methicillin-resistant Staphylococcus aureus (MRSA) endocarditis refractory to standard therapies is an increasingly prevalent clinical entity, and novel agents are needed. Telavancin is a newly developed lipoglycopeptide with potent activity against MRSA, but few data exist regarding its potential role for MRSA endocarditis. The authors report a case of MRSA-persistent bacteremia and endocarditis successfully treated with telavancin and provide a comprehensive review of the literature for its use in the setting of refractory invasive endovascular MRSA infections.

From the *Internal Medicine Department, †Infectious Disease Division, Scripps Mercy Hospital, San Diego; and ‡Infectious Disease Division, Naval Medical Center San Diego, San Diego, CA.

Correspondence to: Nancy Crum-Cianflone, MD, MPH, Scripps Mercy Hospital, 4077 Fifth Ave, San Diego, CA 92103. E-mail: nancy32red@yahoo.com.

The authors have no funding or conflicts of interest to disclose.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.